Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JOOFA
ADC Name
isumab01-C4
Synonyms
lsumab01-C4
   Click to Show/Hide
Organization
MURGITROYD & COMPANY
Drug Status
Investigative
Drug-to-Antibody Ratio
2.6
Antibody Name
Undisclosed
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Compound 4
  Payload Info 
Therapeutic Target
DNA topoisomerase I (TOP1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
DBCO-Azide Click Chemistry Conjugation
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
190
pM
CVCL_0363
Gestational choriocarcinoma
Half Maximal inhibitory Concentration (lC50) 
70000
pM
CVCL_0465
Ovarian serous adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
100000
pM
CVCL_3768
Adenocarcinoma of ovary, Ovarian adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
500000
pM
CVCL_1530
Lung non-small cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 190 pM High FRa expression (FRa +++)
Method Description
A Cell line test on Jeg3
In Vitro Model Gestational choriocarcinoma Jeg3 cells CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 70000 pM High FRa expression (FRa +++)
Method Description
A Cell line test on OVCAR-3
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 100000 pM High FRa expression (FRa +++)
Method Description
A Cell line test on OV90
In Vitro Model Adenocarcinoma of ovary, Ovarian adenocarcinoma OV90 cells CVCL_3768
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 500000 pM High FRa expression (FRa +++)
Method Description
A Cell line test on H2110
In Vitro Model Lung non-small cell carcinoma H2110 cells CVCL_1530
References
Ref 1 Antibody-drug conjugate compounds, and methods of use and treatment